Want to see TSE:MDP full AI Analyst Report?

Medexus Pharmaceuticals Inc (MDP) Price & Analysis

69 Followers

MDP Stock Chart & Stats

C$3.97

C$0.09(2.60%)

At close: Jan 08 4:00 PM EST

C$3.97

C$0.09(2.60%)

Day’s Range― - ―

52-Week RangeC$2.47 - C$5.10

Previous CloseN/A

Volume43.25K

Average Volume (3M)46.68K

Market Cap

C$161.47M

Enterprise ValueC$102.49M

Total Cash (Recent Filing)C$6.52M

Total Debt (Recent Filing)C$22.26M

Price to Earnings (P/E)―

Beta0.86

Next Earnings

Aug 12, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.07

Shares Outstanding31,660,482

10 Day Avg. Volume30,861

30 Day Avg. Volume46,683

Financial Highlights & Ratios

PEG Ratio0.25

Price to Book (P/B)2.06

Price to Sales (P/S)1.02

P/FCF Ratio27.10

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

C$6.00

Price Target Upside51.13% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)0.25

Revenue Forecast (FY)C$114.53M

Bulls Say, Bears Say

Bulls Say

Deleveraging / Balance Sheet HealthMedexus has materially reduced leverage versus prior years, lowering financial risk and interest sensitivity. A healthier capital structure provides durable flexibility to fund commercialization, absorb operational volatility, and negotiate financing on better terms over the next several quarters.

Stable Operating Cash GenerationConsistent positive operating cash flow supports ongoing commercialization and working-capital needs without immediate reliance on external financing. While free cash flow fell, sustained OCF provides a durable buffer to invest in launches and cover near-term obligations over the next 2–6 months.

GRAFAPEX Early Commercial TractionGRAFAPEX shows measurable adoption, reorder behavior and meaningful payer coverage, implying scalable commercial momentum. Management's $30–32M guidance and pathway to >$100M in five years indicate a structural growth engine that can sustainably lift product-level margins and cash generation as rollout continues.

Bears Say

Revenue Decline And Portfolio DisruptionRevenue fell due to loss of legacy product revenue and generic competition, exposing dependence on older assets. This transition creates near-term top-line pressure and visibility challenges until new products like GRAFAPEX scale, leaving a 2–6 month risk window for sustained growth.

Profitability Volatility And Margin PressureMaterial EBITDA and margin deterioration plus a swing to net loss highlight earnings volatility tied to portfolio shifts and launch investments. Until new product revenues scale and SG&A stabilizes, profitability remains susceptible to modest revenue shocks and reimbursement changes over the medium term.

Liquidity Sensitivity From Lower Cash BalancesA sharply reduced cash buffer alongside outstanding debt increases refinancing and operational risk. With limited cash headroom, the company is more exposed to working-capital swings, milestone payments, or unexpected costs and may need to prioritize cash generation or external financing within months.

Medexus Pharmaceuticals Inc News

Medexus: Buy Rating Reiterated as Analyst Sees Leaner Cost Base, Growing U.S. Portfolio and Pipeline Upside Supporting C$6.00 Target Price

Analyst David Martin PhD of Bloom Burton maintained a Buy rating on Medexus Pharmaceuticals Inc, with a price...

3d ago

Medexus Earnings Call: GRAFAPEX Offsets Transition Strain

Medexus Pharmaceuticals (($TSE:MDP)) has held its Q4 earnings call. Read on for the main highlights of the call....

6d ago

MDP Earnings this Week: How Will it Perform?

Medexus Pharmaceuticals (MDP) is scheduled to report 4th quarter earnings on 06/25/2026, after the market closes. Regarding Q4...

10d ago

Medexus Advances U.S. GRAFAPEX Rollout While Streamlining Capital Structure

An update from Medexus Pharmaceuticals Inc ( ($TSE:MDP) ) is now available. Medexus Pharmaceuticals reported continued progress in...

3M ago

Medexus Pharmaceuticals: Channel Headwinds Masking Demand as Strategic Positioning Supports Buy-Rated Risk‑Reward

David Martin PhD, an analyst from Bloom Burton, maintained the Buy rating on Medexus Pharmaceuticals Inc. The associated...

5M ago

Medexus Pharmaceuticals Balances GRAFAPEX Growth With Headwinds

Medexus Pharmaceuticals (($TSE:MDP)) has held its Q3 earnings call. Read on for the main highlights of the call....

5M ago

Is MDP a Buy, Before Earnings?

Medexus Pharmaceuticals (MDP) is scheduled to report 3rd quarter earnings on 02/11/2026, after the market closes. Regarding Q3...

5M ago

Medexus Sets Date for Q3 2026 Earnings Call and Webcast

An update from Medexus Pharmaceuticals Inc ( ($TSE:MDP) ) is now available. Medexus Pharmaceuticals has scheduled a conference...

5M ago

Medexus Pharmaceuticals Inc.: Stable Growth and Promising Outlook Justify Buy Rating

Medexus Pharmaceuticals Inc, the Healthcare sector company, was revisited by a Wall Street analyst on November 14. Analyst...

8M ago

Medexus Secures New Credit Facilities and Plans Share Buyback

Medexus Pharmaceuticals Inc ( ($TSE:MDP) ) has shared an announcement. Medexus Pharmaceuticals announced a new senior secured credit...

8M ago

MDP FAQ

What was Medexus Pharmaceuticals Inc’s price range in the past 12 months?

Medexus Pharmaceuticals Inc lowest stock price was C$2.47 and its highest was C$5.10 in the past 12 months.

What is Medexus Pharmaceuticals Inc’s market cap?

Medexus Pharmaceuticals Inc’s market cap is C$161.47M.

When is Medexus Pharmaceuticals Inc’s upcoming earnings report date?

Medexus Pharmaceuticals Inc’s upcoming earnings report date is Aug 12, 2026 which is in 41 days.

How were Medexus Pharmaceuticals Inc’s earnings last quarter?

Medexus Pharmaceuticals Inc released its earnings results on Jun 25, 2026. The company reported -C$0.114 earnings per share for the quarter, missing the consensus estimate of -C$0.014 by -C$0.099.

Is Medexus Pharmaceuticals Inc overvalued?

According to Wall Street analysts Medexus Pharmaceuticals Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Medexus Pharmaceuticals Inc pay dividends?

Medexus Pharmaceuticals Inc does not currently pay dividends.

What is Medexus Pharmaceuticals Inc’s EPS estimate?

Medexus Pharmaceuticals Inc’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Medexus Pharmaceuticals Inc have?

Medexus Pharmaceuticals Inc has 31,660,482 shares outstanding.

What happened to Medexus Pharmaceuticals Inc’s price movement after its last earnings report?

Medexus Pharmaceuticals Inc reported an EPS of -C$0.114 in its last earnings report, missing expectations of -C$0.014. Following the earnings report the stock price went up 3.96%.

Which hedge fund is a major shareholder of Medexus Pharmaceuticals Inc?

Currently, no hedge funds are holding shares in TSE:MDP

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Medexus Pharmaceuticals Inc Stock Smart Score

Neutral

Fundamentals

Return on Equity

-0.52%

Trailing 12-Months

Asset Growth

-16.89%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Medexus Pharmaceuticals Inc

Medexus Pharmaceuticals Inc. operates as a pharmaceutical company in Canada and the United States. The company focuses on various therapeutic areas comprising allergy, dermatology, hematology, oncology, rheumatology, and rare diseases. Its primary products include IXINITY, an intravenous recombinant factor IX therapeutic for use in patients with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; GRAFAPEX, an injection to treat allogeneic hematopoietic stem cell transplantation in adult and pediatric patients, acute myeloid leukemia (AML), and myelodysplastic syndrome (MDS); and Gleolan, an optical imaging agent for patients with glioma as an adjunct for the visualization of malignant tissue during surgery. The company’s products portfolio also includes Cuvposa, a glycopyrrolate oral solution; Naproxen, a Pediapharm naproxen suspension; Otixal, a ciprofloxacin and flucinolone acetonide; Trispan, a triamcinolone hexacetonide injectable suspension; and Trecondyv, a bifunctional alkylating agent for use as part of a conditioning treatment for patients undergoing allogeneic hematopoietic stem cell transplantation. In addition, it offers over the counter products comprising Nyda, a topical treatment indicated for the eradication of head lice; Relaxa, an osmotic laxative to treat occasional constipation in adults; Oralvisc to reduce joint pain and enhance joint function in osteoarthritis of the knee; and Calcia Calcium and vitamin D products. The company was formerly known as Pediapharm Inc. and changed its name to Medexus Pharmaceuticals Inc. in December 2018. Medexus Pharmaceuticals Inc. was founded in 2000 and is based in Toronto, Canada.

Medexus Pharmaceuticals Inc (MDP) Earnings & Revenues

Historic Earnings Reports

MDP Stock 12 Month Forecast

Average Price Target

C$6.00

▲(51.13% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"C$1","4":"C$4","7":"C$7","2.5":"C$2.5","5.5":"C$5.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">C$6.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">C$6.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">C$6.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,2.5,4,5.5,7],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.1,5.169230769230769,5.2384615384615385,5.3076923076923075,5.3769230769230765,5.446153846153846,5.515384615384615,5.584615384615384,5.653846153846153,5.723076923076923,5.792307692307692,5.861538461538462,5.930769230769231,{"y":6,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.1,5.169230769230769,5.2384615384615385,5.3076923076923075,5.3769230769230765,5.446153846153846,5.515384615384615,5.584615384615384,5.653846153846153,5.723076923076923,5.792307692307692,5.861538461538462,5.930769230769231,{"y":6,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.1,5.169230769230769,5.2384615384615385,5.3076923076923075,5.3769230769230765,5.446153846153846,5.515384615384615,5.584615384615384,5.653846153846153,5.723076923076923,5.792307692307692,5.861538461538462,5.930769230769231,{"y":6,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.17,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.66,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.05,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.56,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.8,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.68,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.91,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.85,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.15,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.28,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.01,"date":1777593600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":3.9,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.1,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >